Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDF7XB)

• Drug Name: SYN120 Drug Info
• Synonyms: Landipirdine; 1000308-25-7; UNII-J0NX985GDI; J0NX985GDI; CHEMBL1082508; RO5025181; RO5025181-000; N-(((1R)-6-(3-fluorobenzenesulfonyl)-1,2,3,4-tetrahydronaphthalen-1-yl)methyl)urea; Landipirdine [USAN]; Landipirdine (USAN/INN); SCHEMBL315956; SYN-120; BDBM50416003; SB18761; D11157; Q27896229; R05025181; R0-5025181; R0-5025181-000; R05025181-000; (R)-[6-(3-Fluoro-benzenesulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl]-urea; [(1R)-6-(3-fluorophenyl)sulfonyl-1,2,3,4-tetrahydronaphthalen-1-yl]methylurea; Urea, N-(((1R)-6-((3-fluorophenyl)sulfonyl)-1,2,3,4-tetrahydro-1-naphthalenyl)methyl)-

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 46220503
  CAS Number: CAS 1000308-25-7
  TTD Drug ID: DMDF7XB

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[3]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[4]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[5]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[5]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[6]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[7]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[4]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[8]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[9]
BVT-74316	DMEP321	Obesity	5B81	Phase 1	[10]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[11]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[12]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[13]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[14]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[15]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[16]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[17]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[18]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[19]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Antagonist	[2]
5-HT 6 receptor (HTR6)	TTJS8PY	5HT6R_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT02258152) SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE) (SYNAPSE). U.S. National Institutes of Health.
• [2] Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
• [3] Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
• [4] 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
• [5] Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
• [6] The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
• [7] PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
• [8] Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
• [9] Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
• [10] Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.
• [11] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [12] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [13] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [14] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [15] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [16] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [18] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [19] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [20] Clinical pipeline report, company report or official report of Lundbeck.